IMV Inc.
BioTech/Drugs - Dartmouth, Nova Scotia, CA
IMV Inc. Details
IMV Inc. is a clinical-stage immuno-oncology company advancing a portfolio of therapies based on the Company’s immune-educating platform: the DPX® technology. Through a differentiated mechanism of action, the DPX® platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. IMV’s lead candidate, maveropepimut-S (MVP-S), delivers antigenic peptides of survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers. MVP-S treatment has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. MVP-S is currently being evaluated in clinical trials for hematologic and solid cancers, including Diffuse Large B Cell Lymphoma (DLBCL) as well as ovarian, bladder and breast cancers. For more information, please connect at: www.imv-inc.com
IMV Inc. Technologies
Email Providers
Outlook
Load Balancers
Apache
Customer Relationship Management
Salesforce
CMS
Sage Intacct
Hosting
Amazon AWS
Other
Mobile Friendly